Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus immunochemotherapy maintenance after first-line therapy in metastatic colorectal cancer
ChiCTR2400081088Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and capecitabine in metastatic colon cancer (mCRC) and colorectal adenocarcinoma (mCRC), sponsored by Union Hospital. Primary endpoint: Progression-free survival. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
bevacizumabcapecitabine
03
Conditions
metastatic colon cancer (mCRC)colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2400081088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081088.